Novo Nordisk's CagriSema Launch in Focus

Dow Jones16:03

0802 GMT - Novo Nordisk stands ready to launch new obesity and diabetes jab CagriSema, a rollout which must prove that a renaissance in obesity injectables is achievable and that semaglutide-patent expiries are surmountable, Berenberg analysts write. Assuming obesity-treatment approval by year-end, Novo stands ready to launch CagriSema in the U.S. in early 2027, the bank says. Novo's injectable business remains lackluster as competitor Eli Lilly continues to dominate market-share gains. At the same time, investor sentiment on the upcoming CagriSema launch remains subdued, it adds. However, Novo delivered solid third-quarter results and a guidance upgrade. Wegovy pill continues to surprise on the upside, and new market launches should see strong growth carry into 2027. The bank has a hold rating on the stock and 305 Danish kroner price target. Shares closed at 275.75 kroner.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment